PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer ca ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

Vor says drug licensed from RemeGen succeeded in Sjögren’s study While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune condition.

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

And while Keytruda's patent protection doesn't start expiring in earnest until 2028, the drugmaker's got a robust developmental pipeline set to replace much of the revenue that will be lost once ...

Trump’s trade deal with the E.U. may lead to higher prices for brand-name drugs in the U.S., including the blockbuster medications Ozempic and Wegovy, experts say.